Tenet Healthcare (NYSE: THC)‘s stock had its “buy” rating reaffirmed by Deutsche Bank in a research note issued on Friday.
A number of other firms have also recently commented on THC. Analysts at CRT Capital upgraded shares of Tenet Healthcare from a “fair value” rating to a “buy” rating in a research note to investors on Friday. They now have a $51.00 price target on the stock. Separately, analysts at RBC Capital raised their price target on shares of Tenet Healthcare from $20.00 to $38.00 in a research note to investors on Thursday. They now have a “sector perform” rating on the stock. Finally, analysts at Jefferies Group reiterated a “buy” rating on shares of Tenet Healthcare in a research note to investors on Monday. They now have a $48.00 price target on the stock, up previously from $26.00.
Tenet Healthcare traded up 3.42% on Friday, hitting $43.19. Tenet Healthcare has a 1-year low of $17.24 and a 1-year high of $41.83. The stock’s 50-day moving average is currently $39.09. The company has a market cap of $4.504 billion and a price-to-earnings ratio of 32.22.
Tenet Healthcare last announced its earnings results on Tuesday, February 26th. The company reported $0.45 EPS for the quarter, missing the Thomson Reuters consensus estimate of $0.68 by $0.23. The company had revenue of $2.33 billion for the quarter, compared to the consensus estimate of $2.34 billion. During the same quarter in the prior year, the company posted $0.10 earnings per share. The company’s quarterly revenue was up 7.6% on a year-over-year basis. Analysts expect that Tenet Healthcare will post $2.79 EPS for the current fiscal year.
Tenet Healthcare Corporation, and its subsidiaries (Tenet) is an investor-owned health care services company whose subsidiaries and affiliates own and operate acute care hospitals, ambulatory surgery centers, diagnostic imaging centers and related health care facilities.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.
